Bloodstream infections associated with a needleless intravenous infusion system in patients receiving home infusion therapy.
OBJECTIVE
To determine risk factors for bloodstream infections (BSIs) in an outbreak among patients receiving home intravenous infusion therapy.


METHODS
Case-control and retrospective cohort studies.


METHODS
Home health agency.


METHODS
Patients receiving home intravenous infusion therapy from Rhode Island Home Therapeutics (RIHT) from January through December 1993.


METHODS
Development of primary BSI.


METHODS
We compared patients with BSI (ie, case patients) with randomly selected noninfected RIHT patients receiving intravenous therapy, conducted a cohort study of all RIHT patients receiving intravenous therapy via a central venous catheter (CVC), and conducted a culture survey of injection cap luminal fluid.


RESULTS
Case patients were more likely than controls to have had therapy via a CVC (11/11 vs 14/32; odds ratio [OR] undefined; P < .001) or total parenteral nutrition and intralipid therapy (TPN/IL) (9/11 vs 3/32; OR, 43.5; 95% confidence interval [CI], 4.9 to 510.0). Among RIHT patients with CVCs, risk factors for BSI were receipt of TPN/IL (9/35 vs 2/67; rate ratio [RR], 8.6; 95% CI, 2.0 to 37.7) or use of a needleless infusion system (10/41 vs 1/61; RR, 14.9; 95% CI, 2.0 to 111.8). Only the combination of both exposures was significantly associated with development of a BSI (P < .001). Luminal fluid from injection caps of needleless devices was significantly more likely to be culture positive than fluid from protected-needle devices (5/23 vs 0/18; RR undefined; P = .04).


CONCLUSIONS
Our data suggest that a needleless device used for TPN/IL was associated with increased risk of BSI when injection caps were changed every 7 days.
Danzig
L E
LE
Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Short
L J
LJ
Collins
K
K
Mahoney
M
M
Sepe
S
S
Bland
L
L
Jarvis
W R
WR
D016022:Case-Control Studies; D002405:Catheterization, Central Venous / Q000009:adverse effects / Q000295:instrumentation; D015331:Cohort Studies; D004866:Equipment Contamination; D018718:Home Infusion Therapy / Q000009:adverse effects* / Q000295:instrumentation*; D006801:Humans; D007262:Infusions, Intravenous / Q000009:adverse effects* / Q000295:instrumentation*; D010289:Parenteral Nutrition, Total / Q000009:adverse effects / Q000295:instrumentation; D012189:Retrospective Studies; D012306:Risk; D018805:Sepsis / Q000209:etiology*